Dysbiosis in the Development of Type I Diabetes and Associated Complications: From Mechanisms to Targeted Gut Microbes Manipulation Therapies

Simple item page
dc.contributor.authorPircalabioru, Gratiela Gradisteanu
dc.contributor.authorCorcionivoschi, Nicolae
dc.contributor.authorGundogdu, Ozan
dc.contributor.authorChifiriuc, Mariana-Carmen
dc.contributor.authorMarutescu, Luminita Gabriela
dc.contributor.authorIspas, Bogden
dc.contributor.authorSavu, Octavian
dc.date.accessioned2021-03-26T14:37:51Z
dc.date.available2021-03-26T14:37:51Z
dc.date.issued2021-03
dc.descriptionPublication history: Accepted - 8 March 2021; Published online - 9 March 2021en_US
dc.description.abstractGlobally, we are facing a worrying increase in type 1 diabetes mellitus (T1DM) incidence, with onset at younger age shedding light on the need to better understand the mechanisms of disease and step-up prevention. Given its implication in immune system development and regulation of metabolism, there is no surprise that the gut microbiota is a possible culprit behind T1DM pathogenesis. Additionally, microbiota manipulation by probiotics, prebiotics, dietary factors and microbiota transplantation can all modulate early host–microbiota interactions by enabling beneficial microbes with protective potential for individuals with T1DM or at high risk of developing T1DM. In this review, we discuss the challenges and perspectives of translating microbiome data into clinical practice. Nevertheless, this progress will only be possible if we focus our interest on developing numerous longitudinal, multicenter, interventional and double-blind randomized clinical trials to confirm their efficacy and safety of these therapeutic approachesen_US
dc.description.sponsorshipThis research was funded by UEFISCDI, project ID PN-III-P1-1.1-PD-2019-0499, grant number 224/2021.en_US
dc.identifierhttp://hdl.handle.net/20.500.12518/227
dc.identifier.citationGradisteanu Pircalabioru, G., Corcionivoschi, N., Gundogdu, O., Chifiriuc, M.-C., Marutescu, L. G., Ispas, B. and Savu, O. (2021) ‘Dysbiosis in the Development of Type I Diabetes and Associated Complications: From Mechanisms to Targeted Gut Microbes Manipulation Therapies’, International Journal of Molecular Sciences. MDPI AG, 22(5), p. 2763. doi: 10.3390/ijms22052763.en_US
dc.identifier.issn1422-0067
dc.identifier.urihttps://doi.org/10.3390/ijms22052763
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.rights© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).en_US
dc.subjectmicrobiotaen_US
dc.subjecttype 1 diabetesen_US
dc.subjectmicrobiomeen_US
dc.subjectdieten_US
dc.subjectdysbiosisen_US
dc.titleDysbiosis in the Development of Type I Diabetes and Associated Complications: From Mechanisms to Targeted Gut Microbes Manipulation Therapiesen_US
dc.typeArticleen_US
dcterms.dateAccepted2021-03-08
dcterms.dateSubmitted2021-02-10

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Dysbiosis in the Development of Type I Diabetes and Associated Complications. From Mechanisms to Targeted Gut Microbes Manipulation Therapies.pdf
Size:
971.99 KB
Format:
Adobe Portable Document Format
Description:
Final published version
Download

Collections

Journal Articles